Juventas (Drug Discovery) Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
22
Juventas (Drug Discovery) General Information
Description
Manufacturer of CAR-T cell therapy drugs and innovative cell biopharmaceuticals designed to treat hematologic malignancies, solid tumors, and autoimmune diseases. The company's manufacturing capabilities utilize humanized CAR-T cell engineering, viral vector construction, automated cell processing, and commercial-scale GMP cell manufacturing, providing specialized hospitals, hematology centers, and clinical researchers with NMPA-approved CD19 CAR-T cell drug products, multi-target cellular immunotherapy drugs, and clinical-stage cell therapy drug pipelines to facilitate targeted treatment for leukemia, lymphoma, and severe autoimmune conditions.
Contact Information
Website
www.juventas.cnCorporate Office
- Building 5, Number 8, Haitai Development Third Road, Huayuan Industrial Park
- Binhai High-tech Zone
- Tianjin, 300384
- China
Corporate Office
- Building 5, Number 8, Haitai Development Third Road, Huayuan Industrial Park
- Binhai High-tech Zone
- Tianjin, 300384
- China
Juventas (Drug Discovery) Timeline
Juventas (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 31-May-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C2) | 25-Jun-2023 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 24-Oct-2022 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 12-Jul-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 30-Sep-2020 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jan-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 01-Jun-2019 | $14.6M | $38.1M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 13-Dec-2018 | $23.5M | $23.5M | Completed | Generating Revenue |
Juventas (Drug Discovery) Comparisons
Industry
Financing
Details
Juventas (Drug Discovery) Competitors (12)
One of Juventas (Drug Discovery)’s 12 competitors is JW Therapeutics, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| JW Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| FosunKairos | Venture Capital-Backed | Shanghai, China | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Juventas (Drug Discovery) Patents
Juventas (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025228181-A1 | Enhanced chimeric antigen receptor and use thereof | Pending | 30-Apr-2024 | ||
| WO-2025108294-A1 | Cd7-targeting humanized antibody, chimeric antigen receptor, and use thereof | Inactive | 21-Nov-2023 | ||
| WO-2025015726-A1 | Antibody against cd19 antibody, antibody against cd22 antibody, and uses thereof | Inactive | 20-Jul-2023 | ||
| WO-2025015726-A9 | Antibody against cd19 antibody, antibody against cd22 antibody, and uses thereof | Inactive | 20-Jul-2023 | ||
| US-20230272069-A1 | Chimeric antigen receptor targeting cd22 and cd19 and application thereof | Pending | 28-Feb-2022 | C07K14/70578 |
Juventas (Drug Discovery) Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Baochuang Capital | Growth/Expansion | Minority | ||
| GDD Industry Fund | Government | Minority | ||
| Guangdong Technology Financial Group | Government | Minority | ||
| Guangzhou Industrial Investment Holding Group | Government | Minority | ||
| Guangzhou Science and Technology Financial Innovation Investment Holding | Venture Capital | Minority |
Juventas (Drug Discovery) FAQs
-
When was Juventas (Drug Discovery) founded?
Juventas (Drug Discovery) was founded in 2018.
-
Where is Juventas (Drug Discovery) headquartered?
Juventas (Drug Discovery) is headquartered in Tianjin, China.
-
What industry is Juventas (Drug Discovery) in?
Juventas (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Juventas (Drug Discovery) a private or public company?
Juventas (Drug Discovery) is a Private company.
-
What is Juventas (Drug Discovery)’s current revenue?
The current revenue for Juventas (Drug Discovery) is .
-
How much funding has Juventas (Drug Discovery) raised over time?
Juventas (Drug Discovery) has raised $180M.
-
Who are Juventas (Drug Discovery)’s investors?
Baochuang Capital, GDD Industry Fund, Guangdong Technology Financial Group, Guangzhou Industrial Investment Holding Group, and Guangzhou Science and Technology Financial Innovation Investment Holding are 5 of 22 investors who have invested in Juventas (Drug Discovery).
-
Who are Juventas (Drug Discovery)’s competitors?
JW Therapeutics, FosunKairos, Corvus Pharmaceuticals, Kite Pharma, and Inovio Pharmaceuticals are some of the 12 competitors of Juventas (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process